News & Updates
Filter by Specialty:
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
byStephen Padilla
Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
Add-on ribociclib continues to triumph in early breast cancer
20 Dec 2023
byAudrey Abella
Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.
Add-on ribociclib continues to triumph in early breast cancer
20 Dec 2023
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
19 Dec 2023
Majority of the patients with heart failure (HF) who have initiated treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) show no change in loop diuretic dose, reports a study.
